Viveve Medical (VIVE) Stock Rating Reaffirmed by Mizuho

Mizuho reaffirmed their buy rating on shares of Viveve Medical (NASDAQ:VIVE) in a research report report published on Thursday. Mizuho currently has a $10.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Ladenburg Thalmann Financial Services reissued a buy rating on shares of Viveve Medical in a research note on Thursday, January 4th. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a buy rating in a research note on Monday, October 23rd. Northland Securities started coverage on shares of Viveve Medical in a research note on Friday, January 5th. They issued an outperform rating and a $8.00 price objective for the company. Finally, ValuEngine lowered shares of Viveve Medical from a sell rating to a strong sell rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Viveve Medical has a consensus rating of Buy and an average price target of $10.00.

Viveve Medical (NASDAQ:VIVE) opened at $4.24 on Thursday. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. Viveve Medical has a 12 month low of $3.75 and a 12 month high of $11.16.

Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The business had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $4.10 million. During the same period in the previous year, the business posted ($0.46) EPS. The company’s revenue for the quarter was up 120.1% compared to the same quarter last year. equities research analysts forecast that Viveve Medical will post -2.05 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers acquired a new stake in Viveve Medical in the second quarter valued at approximately $110,000. JPMorgan Chase & Co. acquired a new stake in Viveve Medical in the second quarter valued at approximately $151,000. Virtu KCG Holdings LLC acquired a new stake in Viveve Medical in the second quarter valued at approximately $169,000. Schwab Charles Investment Management Inc. acquired a new stake in Viveve Medical in the second quarter valued at approximately $189,000. Finally, California State Teachers Retirement System acquired a new stake in Viveve Medical in the second quarter valued at approximately $190,000. 66.89% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://transcriptdaily.com/2018/02/04/viveve-medical-vive-stock-rating-reaffirmed-by-mizuho.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply